查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1916507

全球體外診斷市場：市場規模、份額、成長率、產業分析、按類型、應用和地區劃分的考量、未來預測（2026-2034）

In vitro Diagnostics Market Size, Share, Growth and Global Industry Analysis By Type & Application, Regional Insights and Forecast to 2026-2034
出版日期: | 出版商: Fortune Business Insights Pvt. Ltd. | 英文 290 Pages | 商品交期: 請詢問到貨日

價格

體外診斷 (IVD) 市場成長因子

全球體外診斷 (IVD) 市場規模預計在 2025 年將達到 777.3 億美元，2026 年將成長至 818.3 億美元，到 2034 年將達到 1356.5 億美元，在預測期（2026-2034 年）內將達到 1356.5 億美元，在預測期（2026-2034 年）內複合成長率為 6.50%。憑藉先進的醫療基礎設施、優惠的報銷政策以及主要診斷設備製造商的強大影響力，北美在2025年將以37.70%的市場份額引領全球體外診斷（IVD）市場。

體外診斷設備是用於分析血液、尿液、唾液和組織等生物樣本的醫療診斷工具，其用途包括檢測疾病、監測治療效果和進行健康檢查。據英國體外診斷協會（BIDA）稱，體外診斷檢測影響約70%的臨床決策，凸顯了其在現代醫療保健系統中的關鍵作用。

市場驅動因素

慢性病和傳染病的增加是推動市場成長的主要因素。根據美國疾病管制與預防中心 (CDC) 的數據，2022 年美國結核病病例數將增加 5%，達到 8,300 例。此外，美國國家生物技術資訊中心 (NCBI) 的數據顯示，到 2023 年，全球慢性B型肝炎病毒感染率將達到 3.2%（2.57 億例）。

人口老化將進一步增加所需的檢測數量。在中國，預計到 2023 年，60 歲及以上人口將達到約 2.97 億，這將推動心血管、腎臟和代謝性疾病診斷監測的需求。政府加強支持力度也在推動檢測的普及。 2023 年 10 月，世界衛生組織 (WHO) 發布了《2023 年基本診斷清單》，敦促各國加強初級和二級醫療保健機構的診斷服務。

市場限制因子

新興國家採用此技術受限於高昂的設備和維修成本。 RT-PCR 系統的價格從 15,000 美元到超過 90,000 美元不等，小型醫院和實驗室難以負擔。此外，對熟練人員的需求增加了營運成本，阻礙了資源匱乏地區廣泛採用該技術。

市場機會

分子診斷技術因其高靈敏度和快速檢測能力而展現出巨大的市場機會。 PCR 和次世代定序等技術能夠以極少的樣本量實現早期診斷。 2023 年 3 月，DiaSorin 的 Simplexa COVID-19 和甲型/乙型流感直接檢測試劑盒獲得 FDA 批准，進一步拓展了其分子檢測產品組合。

腫瘤生物標記檢測和個人化醫療計畫的擴展也推動了先進診斷平台的應用。癌症篩檢計畫的擴展和基因組檢測的廣泛應用，正在推動已開發國家和新興國家分子診斷檢測數量的成長。

市場挑戰

一些國家不利的報銷政策限制了檢測的普及。在巴西和墨西哥，針對高級分子檢測的保險覆蓋仍然不足。據美國國家生物技術資訊中心 (NCBI) 稱，罕見疾病參考中心每三個月僅為每位患者提供 142 美元，不足以支付高級基因組檢測的費用。監管的複雜性、供應鏈中斷和激烈的市場競爭進一步加劇了營運方面的挑戰。

市場趨勢

即時檢測 (POC) 因其快速出結果和較低的基礎設施需求而迅速普及。 2023 年 1 月，Cipla 推出了 Cippoint POC 設備，加強了分散式診斷。 2022 年 6 月，BD 的 COVID-19、流感和呼吸道合胞病毒 (RSV) 組合檢測板獲得了 CE 認證，支持了多重檢測的普及。

自動化和人工智慧技術的整合正在提升臨床實驗室的工作流程效率、診斷準確性和樣本處理量。

依細分市場分析

依產品類型

由於慢性病監測和即時檢測 (POC) 試劑盒的高檢測量，試劑和耗材在 2024 年佔據市場主導地位。 2021 年 2 月，賽默飛世爾科技 (Thermo Fisher) 推出了用於高通量檢測的 TaqPath COVID-19 HT 試劑盒。由於自動化升級，例如 BD 公司於 2023 年 6 月推出的 FACSDuet Premium 樣本製備系統，預計設備領域將保持穩定成長。

依科技

由於傳染病和腫瘤檢測的增加，分子診斷將在 2024 年成為主流。 Seegene 於 2023 年 12 月獲得 ISO 45001 PCR 診斷認證。由於代謝性疾病篩檢的增加，臨床化學也穩定發展。

依樣本類型

血液樣本將在 2024 年成為主流。這是因為美國每年進行約 20 億次血液檢測。由於非侵入性診斷技術的創新，尿液和唾液檢測的數量也在增加。

按地點

由於複雜的檢測需求和自動化方面的投資，實驗室將成為主流。由於對快速傳染病篩檢和緊急檢測的需求不斷增長，即時檢測 (POC) 環境正在迅速擴展。

按應用領域

傳染病診斷將在2024年佔據主導地位。根據世界衛生組織估計，2023年全球結核病病例將達1,080萬例。此外，由於基於生物標記的癌症篩檢的普及，腫瘤診斷領域也呈現強勁成長勢頭。

按最終使用者

臨床實驗室將在2024年佔據主導地位，美國約有322,488家實驗室。醫院越來越多地採用糖尿病、妊娠和急診檢測。

區域展望

預計北美地區2025年將達到293.3億美元，2026年將達到309.2億美元，其中美國2026年將達到279.8億美元。歐洲仍將維持第二大市場地位，預計德國2026年將達55億美元，英國將達38.3億美元。亞太地區2026年將達189.4億美元，其次是中國（66.1億美元）、日本（43.2億美元）和印度（33.7億美元）。拉丁美洲市場規模預計在 2026 年達到 62.2 億美元，海灣合作委員會 (GCC) 市場規模預計在 2026 年達到 42.5 億美元。

目錄

第一章：引言

第二章：執行摘要

第三章：市場動態

  • 市場驅動因素
  • 市場限制因素
  • 市場機遇

第四章：關鍵考慮因素

  • 各國和地區主要疾病盛行率（2025 年）
  • 主要公司新產品發布
  • 近期產業趨勢：併購
  • 醫療保健支出概覽：依主要機構劃分國家/地區
  • 技術進步、體外診斷設備及試劑盒
  • COVID-19 對體外診斷市場的影響

第五章 全球體外診斷市場分析：洞察與預測 (2021-2034)

  • 市場分析、洞察與預測：依產品類型劃分
    • 儀器
    • 試劑和耗材
  • 市場分析、洞察與預測：依技術劃分
    • 免疫診斷
      • 酵素連結免疫吸附試驗 (ELISA)
      • 螢光免疫分析 (FIA)
      • 快速偵測
      • 其他
    • 臨床化學
      • 電解質檢測項目
      • 基礎與綜合代謝檢測項目
      • 肝功能檢測
      • 腎功能檢測
      • 血脂檢測
      • 其他
    • 分子診斷
      • 聚合酶鍊式反應 (PCR)
      • 原位雜交
      • DNA定序/次世代定序
      • 其他
    • 血液學
    • 其他
  • 市場分析、洞察與預測：按樣本類型劃分
    • 血液
    • 尿液
    • 唾液
    • 組織
    • 其他
  • 市場分析、洞察與預測：按地點劃分
    • 實驗室
    • 即時偵測 (POC)
  • 市場分析、洞察、及預測：按應用領域
    • 傳染病
    • 心臟病
    • 癌症
    • 消化系統疾病
    • 過敏症
    • 自體免疫疾病
    • 產前篩檢
    • 其他
  • 市場分析、洞察及預測：按最終用戶
    • 臨床實驗室
    • 醫院
    • 診所
    • 其他
  • 市場分析、洞察及預測：按地區
    • 北美
    • 歐洲
    • 亞太地區
    • 拉丁美洲
    • 中東和非洲

第六章 北美體外診斷市場分析：洞察與預測（2021-2034）

  • 依國家/地區
    • 美國
    • 加拿大

第七章：歐洲體外診斷市場分析：洞察與預測（2021-2034）

  • 依國家劃分
    • 德國
    • 英國
    • 法國
    • 義大利
    • 西班牙
    • 斯堪的納維亞半島
    • 歐洲其他地區

第八章：亞太地區體外診斷市場分析：洞察與預測（2021-2034）

  • 依國家劃分
    • 中國
    • 日本
    • 印度
    • 澳大利亞
    • 東南亞
    • 其他地區亞太地區

第九章：拉丁美洲體外診斷市場分析：洞察與預測（2021-2034）

  • 依國家劃分
    • 巴西
    • 墨西哥
    • 拉丁美洲其他地區

第十章：中東與非洲體外診斷市場分析：洞察與預測（2021-2034）

  • 依國家劃分
    • 海灣合作委員會（GCC）成員國
    • 南非
    • 中東和非洲其他地區

第十一章 競爭分析

  • 全球市佔率分析（2025）
  • 主要營運公司概覽市場
    • F. Hoffmann-La Roche Ltd.
    • Abbott
    • Thermo Fisher Scientific Inc.
    • Sysmex Corporation
    • Siemens Healthineers AG
    • BD
    • Seegene Inc.
    • DiaSorin S.p.A.
    • Quest Diagnostics Incorporated
    • Bio-Rad Laboratories, Inc.
Product Code: FBI101443

Growth Factors of in-vitro diagnostics (IVD) Market

The global in-vitro diagnostics (IVD) market size was valued at USD 77.73 billion in 2025 and is expected to grow to USD 81.83 billion in 2026, reaching USD 135.65 billion by 2034, exhibiting a CAGR of 6.50% during the forecast period (2026-2034). North America dominated the global IVD market with a 37.70% market share in 2025, supported by advanced healthcare infrastructure, favorable reimbursement policies, and strong presence of major diagnostic manufacturers.

IVD devices are medical diagnostic tools used to analyze biological samples such as blood, urine, saliva, and tissues for disease detection, therapy monitoring, and health screening. According to the British In-Vitro Diagnostic Association, IVD tests influence nearly 70% of clinical decision-making, highlighting their essential role in modern healthcare systems.

Market Drivers

The increasing prevalence of chronic and infectious diseases is a major growth driver. According to the U.S. CDC, tuberculosis cases in the U.S. increased by 5% to 8,300 cases in 2022. Additionally, global prevalence of chronic Hepatitis B virus infection was estimated at 3.2% or 257 million cases in 2023, according to NCBI data.

Aging populations further increase testing volumes. China had approximately 297 million people aged 60 and above in 2023, increasing demand for diagnostic monitoring of cardiovascular, renal, and metabolic disorders. Rising government support also boosts adoption. In October 2023, the World Health Organization released the 2023 Essential Diagnostics List, encouraging countries to strengthen diagnostic access at primary and secondary healthcare levels.

Market Restraints

High equipment and maintenance costs restrict adoption in emerging economies. RT-PCR systems range from USD 15,000 to over USD 90,000, limiting affordability for small hospitals and laboratories. Additionally, skilled personnel requirements raise operational expenses, restricting penetration in low-resource settings.

Market Opportunities

Molecular diagnostics represents a major opportunity due to higher sensitivity and faster detection capabilities. Techniques such as PCR and next-generation sequencing enable early diagnosis from minimal samples. In March 2023, DiaSorin received FDA approval for Simplexa COVID-19 & Flu A/B Direct assay, expanding molecular testing portfolios.

Growing oncology biomarker testing and personalized medicine initiatives further support adoption of advanced diagnostic platforms. Expanding cancer screening programs and genomic testing are increasing molecular diagnostic volumes across developed and emerging regions.

Market Challenges

Unfavorable reimbursement policies limit test adoption in several countries. In Brazil and Mexico, coverage for advanced molecular tests remains insufficient. According to NCBI, Rare Disease Reference Centers provide only USD 142 per patient every three months, insufficient for advanced genomic testing. Regulatory complexity, supply chain disruptions, and intense market competition further increase operational challenges.

Market Trends

Point-of-care (POC) testing is gaining strong traction due to faster turnaround times and lower infrastructure requirements. In January 2023, Cipla launched Cippoint POC device, strengthening decentralized diagnostics. BD received CE approval in June 2022 for combined COVID, Flu, and RSV panels, supporting multiplex testing adoption.

Technological integration of automation and artificial intelligence is improving workflow efficiency, diagnostic accuracy, and sample throughput in clinical laboratories.

Segmentation Analysis

By Product Type

Reagents and consumables dominated in 2024 due to high testing volumes from chronic disease monitoring and POC kits. In February 2021, Thermo Fisher launched TaqPath COVID-19 HT kit for high-throughput testing. Instruments are expected to grow steadily due to automation upgrades, such as BD's FACSDuet Premium Sample Preparation System launched in June 2023.

By Technique

Molecular diagnostics dominated in 2024 due to increasing infectious disease and oncology testing. Seegene received ISO45001 certification in December 2023 for PCR diagnostics. Clinical chemistry also grows steadily due to rising metabolic disease screening.

By Sample

Blood samples dominated in 2024, supported by approximately 2 billion blood tests performed annually in the U.S. Urine and saliva testing volumes are increasing due to non-invasive diagnostic innovations.

By Setting

Laboratories dominated due to complex testing requirements and automation investments. POC settings are growing rapidly due to rapid infectious disease screening and emergency testing.

By Application

Infectious disease diagnostics dominated in 2024. WHO estimated 10.8 million global TB cases in 2023. Oncology diagnostics also show strong growth due to biomarker-based cancer screening expansion.

By End-User

Clinical laboratories dominated in 2024, supported by approximately 322,488 labs operating in the U.S. Hospitals show rising adoption for diabetes, pregnancy, and emergency testing.

Regional Outlook

North America generated USD 29.33 billion in 2025 and USD 30.92 billion in 2026, led by the U.S. reaching USD 27.98 billion in 2026. Europe remains second-largest, with Germany reaching USD 5.50 billion in 2026 and the U.K. at USD 3.83 billion in 2026. Asia Pacific reached USD 18.94 billion in 2026, with China at USD 6.61 billion, Japan at USD 4.32 billion, and India at USD 3.37 billion. Latin America reached USD 6.22 billion in 2026, while GCC markets reached USD 4.25 billion in 2026.

Competitive Landscape

The market is semi-consolidated, led by Roche, Abbott, Siemens Healthineers, Thermo Fisher Scientific, BD, Sysmex, DiaSorin, and Seegene. Companies focus on product innovation, regulatory approvals, and geographic expansion. In November 2023, Roche launched Elecsys HBeAg quant immunoassay, while Abbott partnered with LifeLabs in September 2023 to expand diagnostic service reach.

Conclusion

The global in-vitro diagnostics (IVD) market demonstrates steady and sustainable growth, expanding from USD 77.73 billion in 2025 to USD 81.83 billion in 2026, and projected to reach USD 135.65 billion by 2034, supported by a 6.50% CAGR during 2026-2034. Market expansion is primarily driven by rising prevalence of chronic and infectious diseases, increasing geriatric populations, and strong dependence of clinical decision-making on laboratory diagnostics, which influences nearly 70% of treatment decisions. North America maintains leadership with a 37.70% share in 2025, supported by strong reimbursement systems and advanced diagnostic infrastructure, while Asia Pacific shows rapid growth due to expanding healthcare access and rising disease burden. Segment-wise, reagents and consumables, molecular diagnostics, blood-based testing, and laboratory settings remain dominant due to high testing volumes and increasing automation. Although high instrument costs, reimbursement limitations, and regulatory complexities continue to challenge market penetration in emerging economies, growing adoption of molecular testing, point-of-care diagnostics, AI-enabled systems, and personalized medicine is strengthening long-term demand. Overall, IVD remains a foundational pillar of modern healthcare delivery, enabling early detection, treatment monitoring, and improved population health outcomes across global healthcare systems.

Segmentation By Product Type

  • Instruments
  • Reagents & Consumables

By Technique

  • Immunodiagnostics
    • Enzyme-linked immunosorbent Assays (ELISA)
    • Fluorescence immunoassay (FIA)
    • Rapid test
    • Others
  • Clinical Chemistry
    • Electrolyte Panel
    • Basic and Comprehensive Metabolic Panels
    • Liver Tests
    • Renal Tests
    • Lipid Panel
    • Others
  • Molecular Diagnostics
    • Polymerase Chain Reaction (PCR)
    • In Situ Hybridization
    • DNA Sequencing & Next-Generation Sequencing
    • Others
  • Hematology
  • Others

By Sample

  • Blood
  • Urine
  • Saliva
  • Tissue
  • Others

By Setting

  • Laboratories
  • Point-of-Care

By Application

  • Infectious Diseases
  • Cardiology
  • Oncology
  • Gastroenterology
  • Allergy
  • Autoimmunity
  • Prenatal Screening
  • Others

By End-user

  • Clinical Laboratories
  • Hospitals
  • Physician's Offices
  • Others

By Region

  • North America (By Product Type, By Technique, By Sample, By Setting, By Application, By End-user, and By Country)
    • U.S. (By Setting)
    • Canada (By Setting)
  • Europe (By Product Type, By Technique, By Sample, By Setting, By Application, By End-user, and By Country/Sub-region)
    • Germany (By Setting)
    • U.K. (By Setting)
    • France (By Setting)
    • Italy (By Setting)
    • Spain (By Setting)
    • Scandinavia (By Setting)
    • Rest of Europe (By Setting)
  • Asia Pacific (By Product Type, By Technique, By Sample, By Setting, By Application, By End-user, and By Country/Sub-region)
    • China (By Setting)
    • Japan (By Setting)
    • India (By Setting)
    • Australia (By Setting)
    • Southeast Asia (By Setting)
    • Rest of Asia Pacific (By Setting)
  • Latin America (By Product Type, By Technique, By Sample, By Setting, By Application, By End-user, and By Country/Sub-region)
    • Brazil (By Setting)
    • Mexico (By Setting)
    • Rest of Latin America (By Setting)
  • Middle East & Africa (By Product Type, By Technique, By Sample, By Setting, By Application, By End-user, and By Country/Sub-region)
    • South Africa (By Setting)
    • GCC (By Setting)
  • Rest of Middle East & Africa (By Setting)

Table of Content

1. Introduction

  • 1.1. Research Scope
  • 1.2. Market Segmentation
  • 1.3. Research Methodology
  • 1.4. Definitions and Assumptions

2. Executive Summary

3. Market Dynamics

  • 3.1. Market Drivers
  • 3.2. Market Restraints
  • 3.3. Market Opportunities

4. Key Insights

  • 4.1. Prevalence of Key Diseases, by Countries/Region in 2025
  • 4.2. New Product Launches by Key Players
  • 4.3. Recent Industry Developments - Mergers & Acquisitions
  • 4.4. Overview of Healthcare Expenditure by Key Countries
  • 4.5. Technological Advancements, IVD Instruments & Kits
  • 4.6. Impact of COVID-19 on the In-Vitro Diagnostics Market

5. Global In-Vitro Diagnostics Market Analysis, Insights and Forecast, 2021-2034

  • 5.1. Market Analysis, Insights and Forecast - By Product Type
    • 5.1.1. Instruments
    • 5.1.2. Reagents & Consumables
  • 5.2. Market Analysis, Insights and Forecast - By Technique
    • 5.2.1. Immunodiagnostics
      • 5.2.1.1. Enzyme-linked immunosorbent Assays (ELISA)
      • 5.2.1.2. Fluorescence immunoassay (FIA)
      • 5.2.1.3. Rapid test
      • 5.2.1.4. Others
    • 5.2.2. Clinical Chemistry
      • 5.2.2.1. Electrolyte Panel
      • 5.2.2.2. Basic and Comprehensive Metabolic Panels
      • 5.2.2.3. Liver Tests
      • 5.2.2.4. Renal Tests
      • 5.2.2.5. Lipid Panel
      • 5.2.2.6. Others
    • 5.2.3. Molecular Diagnostics
      • 5.2.3.1. Polymerase Chain Reaction (PCR)
      • 5.2.3.2. In Situ Hybridization
      • 5.2.3.3. DNA Sequencing & Next-Generation Sequencing
      • 5.2.3.4. Others
    • 5.2.4. Hematology
    • 5.2.5. Others
  • 5.3. Market Analysis, Insights and Forecast - By Sample Type
    • 5.3.1. Blood
    • 5.3.2. Urine
    • 5.3.3. Saliva
    • 5.3.4. Tissue
    • 5.3.5. Others
  • 5.4. Market Analysis, Insights and Forecast - By Setting
    • 5.4.1. Laboratories
    • 5.4.2. Point of care
  • 5.5. Market Analysis, Insights and Forecast - By Application
    • 5.5.1. Infectious Diseases
    • 5.5.2. Cardiology
    • 5.5.3. Oncology
    • 5.5.4. Gastroenterology
    • 5.5.5. Allergy
    • 5.5.6. Autoimmunity
    • 5.5.7. Prenatal Screening
    • 5.5.8. Others
  • 5.6. Market Analysis, Insights and Forecast - By End User
    • 5.6.1. Clinical Laboratories
    • 5.6.2. Hospitals
    • 5.6.3. Physician's Offices
    • 5.6.4. Others
  • 5.7. Market Analysis, Insights and Forecast - By Geography
    • 5.7.1. North America
    • 5.7.2. Europe
    • 5.7.3. Asia Pacific
    • 5.7.4. Latin America
    • 5.7.5. Middle East & Africa

6. North America In-Vitro Diagnostics Market Analysis, Insights and Forecast, 2021-2034

  • 6.1. Market Analysis, Insights and Forecast - By Product Type
    • 6.1.1. Instruments
    • 6.1.2. Reagents & Consumables
  • 6.2. Market Analysis, Insights and Forecast - By Technique
    • 6.2.1. Immunodiagnostics
      • 6.2.1.1. Enzyme-linked immunosorbent Assays (ELISA)
      • 6.2.1.2. Fluorescence immunoassay (FIA)
      • 6.2.1.3. Rapid test
      • 6.2.1.4. Others
    • 6.2.2. Clinical Chemistry
      • 6.2.2.1. Electrolyte Panel
      • 6.2.2.2. Basic and Comprehensive Metabolic Panels
      • 6.2.2.3. Liver Tests
      • 6.2.2.4. Renal Tests
      • 6.2.2.5. Lipid Panel
      • 6.2.2.6. Others
    • 6.2.3. Molecular Diagnostics
      • 6.2.3.1. Polymerase Chain Reaction (PCR)
      • 6.2.3.2. In Situ Hybridization
      • 6.2.3.3. DNA Sequencing & Next-Generation Sequencing
      • 6.2.3.4. Others
    • 6.2.4. Hematology
    • 6.2.5. Others
  • 6.3. Market Analysis, Insights and Forecast - By Sample Type
    • 6.3.1. Blood
    • 6.3.2. Urine
    • 6.3.3. Saliva
    • 6.3.4. Tissue
    • 6.3.5. Others
  • 6.4. Market Analysis, Insights and Forecast - By Setting
    • 6.4.1. Laboratories
    • 6.4.2. Point of care
  • 6.5. Market Analysis, Insights and Forecast - By Application
    • 6.5.1. Infectious Diseases
    • 6.5.2. Cardiology
    • 6.5.3. Oncology
    • 6.5.4. Gastroenterology
    • 6.5.5. Allergy
    • 6.5.6. Autoimmunity
    • 6.5.7. Prenatal Screening
    • 6.5.8. Others
  • 6.6. Market Analysis, Insights and Forecast - By End User
    • 6.6.1. Clinical Laboratories
    • 6.6.2. Hospitals
    • 6.6.3. Physician's Offices
    • 6.6.4. Others
  • 6.7. Market Analysis, Insights and Forecast - By Country
    • 6.7.1. U.S.
      • 6.7.1.1. By Setting
    • 6.7.2. Canada
      • 6.7.2.1. By Setting

7. Europe In-Vitro Diagnostics Market Analysis, Insights and Forecast, 2021-2034

  • 7.1. Market Analysis, Insights and Forecast - By Product Type
    • 7.1.1. Instruments
    • 7.1.2. Reagents & Consumables
  • 7.2. Market Analysis, Insights and Forecast - By Technique
    • 7.2.1. Immunodiagnostics
      • 7.2.1.1. Enzyme-linked immunosorbent Assays (ELISA)
      • 7.2.1.2. Fluorescence immunoassay (FIA)
      • 7.2.1.3. Rapid test
      • 7.2.1.4. Others
    • 7.2.2. Clinical Chemistry
      • 7.2.2.1. Electrolyte Panel
      • 7.2.2.2. Basic and Comprehensive Metabolic Panels
      • 7.2.2.3. Liver Tests
      • 7.2.2.4. Renal Tests
      • 7.2.2.5. Lipid Panel
      • 7.2.2.6. Others
    • 7.2.3. Molecular Diagnostics
      • 7.2.3.1. Polymerase Chain Reaction (PCR)
      • 7.2.3.2. In Situ Hybridization
      • 7.2.3.3. DNA Sequencing & Next-Generation Sequencing
      • 7.2.3.4. Others
    • 7.2.4. Hematology
    • 7.2.5. Others
  • 7.3. Market Analysis, Insights and Forecast - By Sample Type
    • 7.3.1. Blood
    • 7.3.2. Urine
    • 7.3.3. Saliva
    • 7.3.4. Tissue
    • 7.3.5. Others
  • 7.4. Market Analysis, Insights and Forecast - By Setting
    • 7.4.1. Laboratories
    • 7.4.2. Point of care
  • 7.5. Market Analysis, Insights and Forecast - By Application
    • 7.5.1. Infectious Diseases
    • 7.5.2. Cardiology
    • 7.5.3. Oncology
    • 7.5.4. Gastroenterology
    • 7.5.5. Allergy
    • 7.5.6. Autoimmunity
    • 7.5.7. Prenatal Screening
    • 7.5.8. Others
  • 7.6. Market Analysis, Insights and Forecast - By End User
    • 7.6.1. Clinical Laboratories
    • 7.6.2. Hospitals
    • 7.6.3. Physician's Offices
    • 7.6.4. Others
  • 7.7. Market Analysis, Insights and Forecast - By Country/ Sub-region
    • 7.7.1. Germany
      • 7.7.1.1. By Setting
    • 7.7.2. U.K.
      • 7.7.2.1. By Setting
    • 7.7.3. France
      • 7.7.3.1. By Setting
    • 7.7.4. Italy
      • 7.7.4.1. By Setting
    • 7.7.5. Spain
      • 7.7.5.1. By Setting
    • 7.7.6. Scandinavia
      • 7.7.6.1. By Setting
    • 7.7.7. Rest of Europe
      • 7.7.7.1. By Setting

8. Asia Pacific In-Vitro Diagnostics Market Analysis, Insights and Forecast, 2021-2034

  • 8.1. Market Analysis, Insights and Forecast - By Product Type
    • 8.1.1. Instruments
    • 8.1.2. Reagents & Consumables
  • 8.2. Market Analysis, Insights and Forecast - By Technique
    • 8.2.1. Immunodiagnostics
      • 8.2.1.1. Enzyme-linked immunosorbent Assays (ELISA)
      • 8.2.1.2. Fluorescence immunoassay (FIA)
      • 8.2.1.3. Rapid test
      • 8.2.1.4. Others
    • 8.2.2. Clinical Chemistry
      • 8.2.2.1. Electrolyte Panel
      • 8.2.2.2. Basic and Comprehensive Metabolic Panels
      • 8.2.2.3. Liver Tests
      • 8.2.2.4. Renal Tests
      • 8.2.2.5. Lipid Panel
      • 8.2.2.6. Others
    • 8.2.3. Molecular Diagnostics
      • 8.2.3.1. Polymerase Chain Reaction (PCR)
      • 8.2.3.2. In Situ Hybridization
      • 8.2.3.3. DNA Sequencing & Next-Generation Sequencing
      • 8.2.3.4. Others
    • 8.2.4. Hematology
    • 8.2.5. Others
  • 8.3. Market Analysis, Insights and Forecast - By Sample Type
    • 8.3.1. Blood
    • 8.3.2. Urine
    • 8.3.3. Saliva
    • 8.3.4. Tissue
    • 8.3.5. Others
  • 8.4. Market Analysis, Insights and Forecast - By Setting
    • 8.4.1. Laboratories
    • 8.4.2. Point of care
  • 8.5. Market Analysis, Insights and Forecast - By Application
    • 8.5.1. Infectious Diseases
    • 8.5.2. Cardiology
    • 8.5.3. Oncology
    • 8.5.4. Gastroenterology
    • 8.5.5. Allergy
    • 8.5.6. Autoimmunity
    • 8.5.7. Prenatal Screening
    • 8.5.8. Others
  • 8.6. Market Analysis, Insights and Forecast - By End User
    • 8.6.1. Clinical Laboratories
    • 8.6.2. Hospitals
    • 8.6.3. Physician's Offices
    • 8.6.4. Others
  • 8.7. Market Analysis, Insights and Forecast - By Country/ Sub-region
    • 8.7.1. China
      • 8.7.1.1. By Setting
    • 8.7.2. Japan
      • 8.7.2.1. By Setting
    • 8.7.3. India
      • 8.7.3.1. By Setting
    • 8.7.4. Australia
      • 8.7.4.1. By Setting
    • 8.7.5. Southeast Asia
      • 8.7.5.1. By Setting
    • 8.7.6. Rest of Asia Pacific
      • 8.7.6.1. By Setting

9. Latin America In-Vitro Diagnostics Market Analysis, Insights and Forecast, 2021-2034

  • 9.1. Market Analysis, Insights and Forecast - By Product Type
    • 9.1.1. Instruments
    • 9.1.2. Reagents & Consumables
  • 9.2. Market Analysis, Insights and Forecast - By Technique
    • 9.2.1. Immunodiagnostics
      • 9.2.1.1. Enzyme-linked immunosorbent Assays (ELISA)
      • 9.2.1.2. Fluorescence immunoassay (FIA)
      • 9.2.1.3. Rapid test
      • 9.2.1.4. Others
    • 9.2.2. Clinical Chemistry
      • 9.2.2.1. Electrolyte Panel
      • 9.2.2.2. Basic and Comprehensive Metabolic Panels
      • 9.2.2.3. Liver Tests
      • 9.2.2.4. Renal Tests
      • 9.2.2.5. Lipid Panel
      • 9.2.2.6. Others
    • 9.2.3. Molecular Diagnostics
      • 9.2.3.1. Polymerase Chain Reaction (PCR)
      • 9.2.3.2. In Situ Hybridization
      • 9.2.3.3. DNA Sequencing & Next-Generation Sequencing
      • 9.2.3.4. Others
    • 9.2.4. Hematology
    • 9.2.5. Others
  • 9.3. Market Analysis, Insights and Forecast - By Sample Type
    • 9.3.1. Blood
    • 9.3.2. Urine
    • 9.3.3. Saliva
    • 9.3.4. Tissue
    • 9.3.5. Others
  • 9.4. Market Analysis, Insights and Forecast - By Setting
    • 9.4.1. Laboratories
    • 9.4.2. Point of care
  • 9.5. Market Analysis, Insights and Forecast - By Application
    • 9.5.1. Infectious Diseases
    • 9.5.2. Cardiology
    • 9.5.3. Oncology
    • 9.5.4. Gastroenterology
    • 9.5.5. Allergy
    • 9.5.6. Autoimmunity
    • 9.5.7. Prenatal Screening
    • 9.5.8. Others
  • 9.6. Market Analysis, Insights and Forecast - By End User
    • 9.6.1. Clinical Laboratories
    • 9.6.2. Hospitals
    • 9.6.3. Physician's Offices
    • 9.6.4. Others
  • 9.7. Market Analysis, Insights and Forecast - By Country/ Sub-region
    • 9.7.1. Brazil
      • 9.7.1.1. By Setting
    • 9.7.2. Mexico
      • 9.7.2.1. By Setting
    • 9.7.3. Rest of Latin America
      • 9.7.3.1. By Setting

10. Middle East & Africa In-Vitro Diagnostics Market Analysis, Insights and Forecast, 2021-2034

  • 10.1. Market Analysis, Insights and Forecast - By Product Type
    • 10.1.1. Instruments
    • 10.1.2. Reagents & Consumables
  • 10.2. Market Analysis, Insights and Forecast - By Technique
    • 10.2.1. Immunodiagnostics
      • 10.2.1.1. Enzyme-linked immunosorbent Assays (ELISA)
      • 10.2.1.2. Fluorescence immunoassay (FIA)
      • 10.2.1.3. Rapid test
      • 10.2.1.4. Others
    • 10.2.2. Clinical Chemistry
      • 10.2.2.1. Electrolyte Panel
      • 10.2.2.2. Basic and Comprehensive Metabolic Panels
      • 10.2.2.3. Liver Tests
      • 10.2.2.4. Renal Tests
      • 10.2.2.5. Lipid Panel
      • 10.2.2.6. Others
    • 10.2.3. Molecular Diagnostics
      • 10.2.3.1. Polymerase Chain Reaction (PCR)
      • 10.2.3.2. In Situ Hybridization
      • 10.2.3.3. DNA Sequencing & Next-Generation Sequencing
      • 10.2.3.4. Others
    • 10.2.4. Hematology
    • 10.2.5. Others
  • 10.3. Market Analysis, Insights and Forecast - By Sample Type
    • 10.3.1. Blood
    • 10.3.2. Urine
    • 10.3.3. Saliva
    • 10.3.4. Tissue
    • 10.3.5. Others
  • 10.4. Market Analysis, Insights and Forecast - By Setting
    • 10.4.1. Laboratories
    • 10.4.2. Point of care
  • 10.5. Market Analysis, Insights and Forecast - By Application
    • 10.5.1. Infectious Diseases
    • 10.5.2. Cardiology
    • 10.5.3. Oncology
    • 10.5.4. Gastroenterology
    • 10.5.5. Allergy
    • 10.5.6. Autoimmunity
    • 10.5.7. Prenatal Screening
    • 10.5.8. Others
  • 10.6. Market Analysis, Insights and Forecast - By End User
    • 10.6.1. Clinical Laboratories
    • 10.6.2. Hospitals
    • 10.6.3. Physician's Offices
    • 10.6.4. Others
  • 10.7. Market Analysis, Insights and Forecast - By Country/ Sub-region
    • 10.7.1. GCC
      • 10.7.1.1. By Setting
    • 10.7.2. South Africa
      • 10.7.2.1. By Setting
    • 10.7.3. Rest of Middle East & Africa
      • 10.7.3.1. By Setting

11. Competitive Analysis

  • 11.1. Global Market Share Analysis (2025)
  • 11.2. Profiles of Players Operating in the Market
    • 11.2.1. F. Hoffmann-La Roche Ltd.
      • 11.2.1.1. Overview
      • 11.2.1.2. Products
      • 11.2.1.3. SWOT Analysis
      • 11.2.1.4. Recent Developments
      • 11.2.1.5. Strategies
      • 11.2.1.6. Financials (Based on Availability)
    • 11.2.2. Abbott
      • 11.2.2.1. Overview
      • 11.2.2.2. Products
      • 11.2.2.3. SWOT Analysis
      • 11.2.2.4. Recent Developments
      • 11.2.2.5. Strategies
      • 11.2.2.6. Financials (Based on Availability)
    • 11.2.3. Thermo Fisher Scientific Inc.
      • 11.2.3.1. Overview
      • 11.2.3.2. Products
      • 11.2.3.3. SWOT Analysis
      • 11.2.3.4. Recent Developments
      • 11.2.3.5. Strategies
      • 11.2.3.6. Financials (Based on Availability)
    • 11.2.4. Sysmex Corporation
      • 11.2.4.1. Overview
      • 11.2.4.2. Products
      • 11.2.4.3. SWOT Analysis
      • 11.2.4.4. Recent Developments
      • 11.2.4.5. Strategies
      • 11.2.4.6. Financials (Based on Availability)
    • 11.2.5. Siemens Healthineers AG
      • 11.2.5.1. Overview
      • 11.2.5.2. Products
      • 11.2.5.3. SWOT Analysis
      • 11.2.5.4. Recent Developments
      • 11.2.5.5. Strategies
      • 11.2.5.6. Financials (Based on Availability)
    • 11.2.6. BD
      • 11.2.6.1. Overview
      • 11.2.6.2. Products
      • 11.2.6.3. SWOT Analysis
      • 11.2.6.4. Recent Developments
      • 11.2.6.5. Strategies
      • 11.2.6.6. Financials (Based on Availability)
    • 11.2.7. Seegene Inc.
      • 11.2.7.1. Overview
      • 11.2.7.2. Products
      • 11.2.7.3. SWOT Analysis
      • 11.2.7.4. Recent Developments
      • 11.2.7.5. Strategies
      • 11.2.7.6. Financials (Based on Availability)
    • 11.2.8. DiaSorin S.p.A.
      • 11.2.8.1. Overview
      • 11.2.8.2. Products
      • 11.2.8.3. SWOT Analysis
      • 11.2.8.4. Recent Developments
      • 11.2.8.5. Strategies
      • 11.2.8.6. Financials (Based on Availability)
    • 11.2.9. Quest Diagnostics Incorporated
      • 11.2.9.1. Overview
      • 11.2.9.2. Products
      • 11.2.9.3. SWOT Analysis
      • 11.2.9.4. Recent Developments
      • 11.2.9.5. Strategies
      • 11.2.9.6. Financials (Based on Availability)
    • 11.2.10. Bio-Rad Laboratories, Inc.
      • 11.2.10.1. Overview
      • 11.2.10.2. Products
      • 11.2.10.3. SWOT Analysis
      • 11.2.10.4. Recent Developments
      • 11.2.10.5. Strategies
      • 11.2.10.6. Financials (Based on Availability)

List of Tables

  • Table 1: Global In-vitro Diagnostics Market Revenue (USD billion) Forecast, by Product Type, 2021-2034
  • Table 2: Global In-vitro Diagnostics Market Revenue (USD billion) Forecast, by Technique, 2021-2034
  • Table 3: Global In-vitro Diagnostics Market Revenue (USD billion) Forecast, by Immunodiagnostics, 2021-2034
  • Table 4: Global In-vitro Diagnostics Market Revenue (USD billion) Forecast, by Clinical Chemistry, 2021-2034
  • Table 5: Global In-vitro Diagnostics Market Revenue (USD billion) Forecast, by Molecular Diagnostics, 2021-2034
  • Table 6: Global In-vitro Diagnostics Market Revenue (USD billion) Forecast, by Sample Type, 2021-2034
  • Table 7: Global In-vitro Diagnostics Market Revenue (USD billion) Forecast, by Setting, 2021-2034
  • Table 8: Global In-vitro Diagnostics Market Revenue (USD billion) Forecast, by Application, 2021-2034
  • Table 9: Global In-vitro Diagnostics Market Revenue (USD billion) Forecast, by End User, 2021-2034
  • Table 10: Global In-vitro Diagnostics Market Revenue (USD billion) Forecast, by Region, 2021-2034
  • Table 11: North America In-vitro Diagnostics Market Revenue (USD billion) Forecast, by Product Type, 2021-2034
  • Table 12: North America In-vitro Diagnostics Market Revenue (USD billion) Forecast, by Technique, 2021-2034
  • Table 13: North America In-vitro Diagnostics Market Revenue (USD billion) Forecast, by Immunodiagnostics, 2021-2034
  • Table 14: North America In-vitro Diagnostics Market Revenue (USD billion) Forecast, by Clinical Chemistry, 2021-2034
  • Table 15: North America In-vitro Diagnostics Market Revenue (USD billion) Forecast, by Molecular Diagnostics, 2021-2034
  • Table 16: North America In-vitro Diagnostics Market Revenue (USD billion) Forecast, by Sample Type, 2021-2034
  • Table 17: North America In-vitro Diagnostics Market Revenue (USD billion) Forecast, by Setting, 2021-2034
  • Table 18: North America In-vitro Diagnostics Market Revenue (USD billion) Forecast, by Application, 2021-2034
  • Table 19: North America In-vitro Diagnostics Market Revenue (USD billion) Forecast, by End User, 2021-2034
  • Table 20: North America In-vitro Diagnostics Market Revenue (USD billion) Forecast, By Country, 2021-2034
  • Table 21: U.S. In-vitro Diagnostics Market Revenue (USD billion) Forecast, by Setting, 2021-2034
  • Table 22: Canada In-vitro Diagnostics Market Revenue (USD billion) Forecast, by Setting, 2021-2034
  • Table 23: Europe In-vitro Diagnostics Market Revenue (USD billion) Forecast, by Product Type, 2021-2034
  • Table 24: Europe In-vitro Diagnostics Market Revenue (USD billion) Forecast, by Technique, 2021-2034
  • Table 25: Europe In-vitro Diagnostics Market Revenue (USD billion) Forecast, by Immunodiagnostics, 2021-2034
  • Table 26: Europe In-vitro Diagnostics Market Revenue (USD billion) Forecast, by Clinical Chemistry, 2021-2034
  • Table 27: Europe In-vitro Diagnostics Market Revenue (USD billion) Forecast, by Molecular Diagnostics, 2021-2034
  • Table 28: Europe In-vitro Diagnostics Market Revenue (USD billion) Forecast, by Sample Type, 2021-2034
  • Table 29: Europe In-vitro Diagnostics Market Revenue (USD billion) Forecast, by Setting, 2021-2034
  • Table 30: Europe In-vitro Diagnostics Market Revenue (USD billion) Forecast, by Application, 2021-2034
  • Table 31: Europe In-vitro Diagnostics Market Revenue (USD billion) Forecast, by End User, 2021-2034
  • Table 32: Europe In-vitro Diagnostics Market Revenue (USD billion) Forecast, By Country/ Sub-region, 2021-2034
  • Table 33: Germany In-vitro Diagnostics Market Revenue (USD billion) Forecast, by Setting, 2021-2034
  • Table 34: U.K. In-vitro Diagnostics Market Revenue (USD billion) Forecast, by Setting, 2021-2034
  • Table 35: France In-vitro Diagnostics Market Revenue (USD billion) Forecast, by Setting, 2021-2034
  • Table 36: Italy In-vitro Diagnostics Market Revenue (USD billion) Forecast, by Setting, 2021-2034
  • Table 37: Spain In-vitro Diagnostics Market Revenue (USD billion) Forecast, by Setting, 2021-2034
  • Table 38: Scandinavia In-vitro Diagnostics Market Revenue (USD billion) Forecast, by Setting, 2021-2034
  • Table 39: Rest of Europe In-vitro Diagnostics Market Revenue (USD billion) Forecast, by Setting, 2021-2034
  • Table 40: Asia Pacific In-vitro Diagnostics Market Revenue (USD billion) Forecast, by Product Type, 2021-2034
  • Table 41: Asia Pacific In-vitro Diagnostics Market Revenue (USD billion) Forecast, by Technique, 2021-2034
  • Table 42: Asia Pacific In-vitro Diagnostics Market Revenue (USD billion) Forecast, by Immunodiagnostics, 2021-2034
  • Table 43: Asia Pacific In-vitro Diagnostics Market Revenue (USD billion) Forecast, by Clinical Chemistry, 2021-2034
  • Table 44: Asia Pacific In-vitro Diagnostics Market Revenue (USD billion) Forecast, by Molecular Diagnostics, 2021-2034
  • Table 45: Asia Pacific In-vitro Diagnostics Market Revenue (USD billion) Forecast, by Sample Type, 2021-2034
  • Table 46: Asia Pacific In-vitro Diagnostics Market Revenue (USD billion) Forecast, by Setting, 2021-2034
  • Table 47: Asia Pacific In-vitro Diagnostics Market Revenue (USD billion) Forecast, by Application, 2021-2034
  • Table 48: Asia Pacific In-vitro Diagnostics Market Revenue (USD billion) Forecast, by End User, 2021-2034
  • Table 49: Asia Pacific In-vitro Diagnostics Market Revenue (USD billion) Forecast, By Country/ Sub-region, 2021-2034
  • Table 50: China In-vitro Diagnostics Market Revenue (USD billion) Forecast, by Setting, 2021-2034
  • Table 51: Japan In-vitro Diagnostics Market Revenue (USD billion) Forecast, by Setting, 2021-2034
  • Table 52: India In-vitro Diagnostics Market Revenue (USD billion) Forecast, by Setting, 2021-2034
  • Table 53: Australia In-vitro Diagnostics Market Revenue (USD billion) Forecast, by Setting, 2021-2034
  • Table 54: Southeast Asia In-vitro Diagnostics Market Revenue (USD billion) Forecast, by Setting, 2021-2034
  • Table 55: Rest of Asia Pacific In-vitro Diagnostics Market Revenue (USD billion) Forecast, by Setting, 2021-2034
  • Table 56: Latin America In-vitro Diagnostics Market Revenue (USD billion) Forecast, by Product Type, 2021-2034
  • Table 57: Latin America In-vitro Diagnostics Market Revenue (USD billion) Forecast, by Technique, 2021-2034
  • Table 58: Latin America In-vitro Diagnostics Market Revenue (USD billion) Forecast, by Immunodiagnostics, 2021-2034
  • Table 59: Latin America In-vitro Diagnostics Market Revenue (USD billion) Forecast, by Clinical Chemistry, 2021-2034
  • Table 60: Latin America In-vitro Diagnostics Market Revenue (USD billion) Forecast, by Molecular Diagnostics, 2021-2034
  • Table 61: Latin America In-vitro Diagnostics Market Revenue (USD billion) Forecast, by Sample Type, 2021-2034
  • Table 62: Latin America In-vitro Diagnostics Market Revenue (USD billion) Forecast, by Setting, 2021-2034
  • Table 63: Latin America In-vitro Diagnostics Market Revenue (USD billion) Forecast, by Application, 2021-2034
  • Table 64: Latin America In-vitro Diagnostics Market Revenue (USD billion) Forecast, by End User, 2021-2034
  • Table 65: Latin America In-vitro Diagnostics Market Revenue (USD billion) Forecast, By Country/ Sub-region, 2021-2034
  • Table 66: Brazil In-vitro Diagnostics Market Revenue (USD billion) Forecast, by Setting, 2021-2034
  • Table 67: Mexico In-vitro Diagnostics Market Revenue (USD billion) Forecast, by Setting, 2021-2034
  • Table 68: Rest of Latin America In-vitro Diagnostics Market Revenue (USD billion) Forecast, by Setting, 2021-2034
  • Table 69: Middle East & Africa In-vitro Diagnostics Market Revenue (USD billion) Forecast, by Product Type, 2021-2034
  • Table 70: Middle East & Africa In-vitro Diagnostics Market Revenue (USD billion) Forecast, by Technique, 2021-2034
  • Table 71: Middle East & Africa In-vitro Diagnostics Market Revenue (USD billion) Forecast, by Immunodiagnostics, 2021-2034
  • Table 72: Middle East & Africa In-vitro Diagnostics Market Revenue (USD billion) Forecast, by Clinical Chemistry, 2021-2034
  • Table 73: Middle East & Africa In-vitro Diagnostics Market Revenue (USD billion) Forecast, by Molecular Diagnostics, 2021-2034
  • Table 74: Middle East & Africa In-vitro Diagnostics Market Revenue (USD billion) Forecast, by Sample Type, 2021-2034
  • Table 75: Middle East & Africa In-vitro Diagnostics Market Revenue (USD billion) Forecast, by Setting, 2021-2034
  • Table 76: Middle East & Africa In-vitro Diagnostics Market Revenue (USD billion) Forecast, by Application, 2021-2034
  • Table 77: Middle East & Africa In-vitro Diagnostics Market Revenue (USD billion) Forecast, by End User, 2021-2034
  • Table 78: Middle East & Africa In-vitro Diagnostics Market Revenue (USD billion) Forecast, By Country/ Sub-region, 2021-2034
  • Table 79: GCC In-vitro Diagnostics Market Revenue (USD billion) Forecast, by Setting, 2021-2034
  • Table 80: South Africa In-vitro Diagnostics Market Revenue (USD billion) Forecast, by Setting, 2021-2034
  • Table 81: Rest of Middle East & Africa In-vitro Diagnostics Market Revenue (USD billion) Forecast, by Setting, 2021-2034

List of Figures

  • Figure 1: Global In-vitro Diagnostics Market Revenue Breakdown (USD billion, %) by Region, 2025 & 2034
  • Figure 2: Global In-vitro Diagnostics Market Value Share (%), by Product Type, 2025 & 2034
  • Figure 3: Global In-vitro Diagnostics Market Value Share (%), by Technique, 2025 & 2034
  • Figure 4: Global In-vitro Diagnostics Market Value Share (%), by Sample Type, 2025 & 2034
  • Figure 5: Global In-vitro Diagnostics Market Value Share (%), by Setting, 2025 & 2034
  • Figure 6: Global In-vitro Diagnostics Market Value Share (%), by Application, 2025 & 2034
  • Figure 7: Global In-vitro Diagnostics Market Value Share (%), by End User, 2025 & 2034
  • Figure 8: Global In-vitro Diagnostics Market Value Share (%), by Region, 2025 & 2034
  • Figure 9: North America In-vitro Diagnostics Market Value (USD billion), by Product Type, 2025 & 2034
  • Figure 10: North America In-vitro Diagnostics Market Value Share (%), by Product Type, 2025
  • Figure 11: North America In-vitro Diagnostics Market Value (USD billion), by Technique, 2025 & 2034
  • Figure 12: North America In-vitro Diagnostics Market Value Share (%), by Technique, 2025
  • Figure 13: North America In-vitro Diagnostics Market Value (USD billion), by Sample Type, 2025 & 2034
  • Figure 14: North America In-vitro Diagnostics Market Value Share (%), by Sample Type, 2025
  • Figure 15: North America In-vitro Diagnostics Market Value (USD billion), by Setting, 2025 & 2034
  • Figure 16: North America In-vitro Diagnostics Market Value Share (%), by Setting, 2025
  • Figure 17: North America In-vitro Diagnostics Market Value (USD billion), by Application, 2025 & 2034
  • Figure 18: North America In-vitro Diagnostics Market Value Share (%), by Application, 2025
  • Figure 19: North America In-vitro Diagnostics Market Value (USD billion), by End User, 2025 & 2034
  • Figure 20: North America In-vitro Diagnostics Market Value Share (%), by End User, 2025
  • Figure 21: North America In-vitro Diagnostics Market Value (USD billion), By Country, 2025 & 2034
  • Figure 22: North America In-vitro Diagnostics Market Value Share (%), By Country, 2025
  • Figure 23: Europe In-vitro Diagnostics Market Value (USD billion), by Product Type, 2025 & 2034
  • Figure 24: Europe In-vitro Diagnostics Market Value Share (%), by Product Type, 2025
  • Figure 25: Europe In-vitro Diagnostics Market Value (USD billion), by Technique, 2025 & 2034
  • Figure 26: Europe In-vitro Diagnostics Market Value Share (%), by Technique, 2025
  • Figure 27: Europe In-vitro Diagnostics Market Value (USD billion), by Sample Type, 2025 & 2034
  • Figure 28: Europe In-vitro Diagnostics Market Value Share (%), by Sample Type, 2025
  • Figure 29: Europe In-vitro Diagnostics Market Value (USD billion), by Setting, 2025 & 2034
  • Figure 30: Europe In-vitro Diagnostics Market Value Share (%), by Setting, 2025
  • Figure 31: Europe In-vitro Diagnostics Market Value (USD billion), by Application, 2025 & 2034
  • Figure 32: Europe In-vitro Diagnostics Market Value Share (%), by Application, 2025
  • Figure 33: Europe In-vitro Diagnostics Market Value (USD billion), by End User, 2025 & 2034
  • Figure 34: Europe In-vitro Diagnostics Market Value Share (%), by End User, 2025
  • Figure 35: Europe In-vitro Diagnostics Market Value (USD billion), By Country/ Sub-region, 2025 & 2034
  • Figure 36: Europe In-vitro Diagnostics Market Value Share (%), By Country/ Sub-region, 2025
  • Figure 37: Asia Pacific In-vitro Diagnostics Market Value (USD billion), by Product Type, 2025 & 2034
  • Figure 38: Asia Pacific In-vitro Diagnostics Market Value Share (%), by Product Type, 2025
  • Figure 39: Asia Pacific In-vitro Diagnostics Market Value (USD billion), by Technique, 2025 & 2034
  • Figure 40: Asia Pacific In-vitro Diagnostics Market Value Share (%), by Technique, 2025
  • Figure 41: Asia Pacific In-vitro Diagnostics Market Value (USD billion), by Sample Type, 2025 & 2034
  • Figure 42: Asia Pacific In-vitro Diagnostics Market Value Share (%), by Sample Type, 2025
  • Figure 43: Asia Pacific In-vitro Diagnostics Market Value (USD billion), by Setting, 2025 & 2034
  • Figure 44: Asia Pacific In-vitro Diagnostics Market Value Share (%), by Setting, 2025
  • Figure 45: Asia Pacific In-vitro Diagnostics Market Value (USD billion), by Application, 2025 & 2034
  • Figure 46: Asia Pacific In-vitro Diagnostics Market Value Share (%), by Application, 2025
  • Figure 47: Asia Pacific In-vitro Diagnostics Market Value (USD billion), by End User, 2025 & 2034
  • Figure 48: Asia Pacific In-vitro Diagnostics Market Value Share (%), by End User, 2025
  • Figure 49: Asia Pacific In-vitro Diagnostics Market Value (USD billion), By Country/ Sub-region, 2025 & 2034
  • Figure 50: Asia Pacific In-vitro Diagnostics Market Value Share (%), By Country/ Sub-region, 2025
  • Figure 51: Latin America In-vitro Diagnostics Market Value (USD billion), by Product Type, 2025 & 2034
  • Figure 52: Latin America In-vitro Diagnostics Market Value Share (%), by Product Type, 2025
  • Figure 53: Latin America In-vitro Diagnostics Market Value (USD billion), by Technique, 2025 & 2034
  • Figure 54: Latin America In-vitro Diagnostics Market Value Share (%), by Technique, 2025
  • Figure 55: Latin America In-vitro Diagnostics Market Value (USD billion), by Sample Type, 2025 & 2034
  • Figure 56: Latin America In-vitro Diagnostics Market Value Share (%), by Sample Type, 2025
  • Figure 57: Latin America In-vitro Diagnostics Market Value (USD billion), by Setting, 2025 & 2034
  • Figure 58: Latin America In-vitro Diagnostics Market Value Share (%), by Setting, 2025
  • Figure 59: Latin America In-vitro Diagnostics Market Value (USD billion), by Application, 2025 & 2034
  • Figure 60: Latin America In-vitro Diagnostics Market Value Share (%), by Application, 2025
  • Figure 61: Latin America In-vitro Diagnostics Market Value (USD billion), by End User, 2025 & 2034
  • Figure 62: Latin America In-vitro Diagnostics Market Value Share (%), by End User, 2025
  • Figure 63: Latin America In-vitro Diagnostics Market Value (USD billion), By Country/ Sub-region, 2025 & 2034
  • Figure 64: Latin America In-vitro Diagnostics Market Value Share (%), By Country/ Sub-region, 2025
  • Figure 65: Middle East & Africa In-vitro Diagnostics Market Value (USD billion), by Product Type, 2025 & 2034
  • Figure 66: Middle East & Africa In-vitro Diagnostics Market Value Share (%), by Product Type, 2025
  • Figure 67: Middle East & Africa In-vitro Diagnostics Market Value (USD billion), by Technique, 2025 & 2034
  • Figure 68: Middle East & Africa In-vitro Diagnostics Market Value Share (%), by Technique, 2025
  • Figure 69: Middle East & Africa In-vitro Diagnostics Market Value (USD billion), by Sample Type, 2025 & 2034
  • Figure 70: Middle East & Africa In-vitro Diagnostics Market Value Share (%), by Sample Type, 2025
  • Figure 71: Middle East & Africa In-vitro Diagnostics Market Value (USD billion), by Setting, 2025 & 2034
  • Figure 72: Middle East & Africa In-vitro Diagnostics Market Value Share (%), by Setting, 2025
  • Figure 73: Middle East & Africa In-vitro Diagnostics Market Value (USD billion), by Application, 2025 & 2034
  • Figure 74: Middle East & Africa In-vitro Diagnostics Market Value Share (%), by Application, 2025
  • Figure 75: Middle East & Africa In-vitro Diagnostics Market Value (USD billion), by End User, 2025 & 2034
  • Figure 76: Middle East & Africa In-vitro Diagnostics Market Value Share (%), by End User, 2025
  • Figure 77: Middle East & Africa In-vitro Diagnostics Market Value (USD billion), By Country/ Sub-region, 2025 & 2034
  • Figure 78: Middle East & Africa In-vitro Diagnostics Market Value Share (%), By Country/ Sub-region, 2025
  • Figure 79: Global In-vitro Diagnostics Market Share (%), By Company, 2025